The results of the Phase III MURANO trial (NCT02005471) were important to address a number of unanswered questions surrounding the use of venetoclax. Here, Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses the first results of theMURANO study of venetoclax plus rituximab vs. bendamustine plus rituximab for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Prof. Kater highlights the promising results, which demonstrate that this combination has the potential to provide an important new chemotherapy-free option for patients with previously treated CLL. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,
